Takeda Pharmaceutical Company Ltd
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Clinical Trials
1.3k
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1009 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4
- First Posted Date
- 2025-07-06
- Last Posted Date
- 2025-07-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 11
- Registration Number
- NCT07052682
- Locations
- 🇺🇸
Arizona Liver Health, Chandler, Arizona, United States
🇺🇸Adobe Clinical Research, LLC, Tucson, Arizona, United States
🇺🇸Southern California Research Center, Coronado, California, United States
A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults
- Conditions
- Dengue Fever
- Interventions
- Biological: Tetravalent Dengue Vaccine (TDV)
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 496
- Registration Number
- NCT07047521
A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea
- Conditions
- Colorectal Cancer
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 600
- Registration Number
- NCT07035886
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Conditions
- Multiple MyelomaSecondary Immunodeficiency
- Interventions
- Biological: IGI, 10%
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 183
- Registration Number
- NCT06980480
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: Placebo to match zasocitinibDrug: Placebo to match deucravacitinib
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 600
- Registration Number
- NCT06973291
- Prev
- 1
- 2
- 3
- 4
- 5
- 198
- Next
News
Hansa Biopharma Appoints Dr. Richard Philipson as Chief Medical Officer to Lead Next Development Phase
Hansa Biopharma has appointed Dr. Richard Philipson as Chief Medical Officer effective July 14, bringing over 25 years of industry experience to the commercial-stage biopharmaceutical company.
Ascentage Pharma Strengthens Leadership Team with New CFO and Senior VP Appointments
Ascentage Pharma appointed Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance to support the company's global expansion strategy.
FDA Approves Takeda's GAMMAGARD LIQUID ERC, First Ready-to-Use Low IgA Immunoglobulin Therapy for Primary Immunodeficiency
The U.S. FDA has approved GAMMAGARD LIQUID ERC as the only ready-to-use liquid immunoglobulin therapy with low IgA content for primary immunodeficiency treatment in patients aged two and older.
TC Biopharm Leads Gamma Delta T Cell Therapy Development with Over 25 Clinical Programs Worldwide
TC Biopharm's OmnImmune is advancing through a pivotal Phase 2/3 trial for acute myeloid leukemia, representing one of the most advanced gamma delta T cell therapies globally.
CNS Oligonucleotide Licensing Deals Surge 339% to $2.81 Billion in 2024
Licensing agreements for CNS-targeted oligonucleotide therapeutics increased 339% from 2023 to 2024, reaching $2.81 billion in total deal value according to GlobalData's analysis.
CMV Treatment Pipeline Expands with 20+ Therapies from Leading Pharmaceutical Companies
DelveInsight's 2025 assessment reveals 15+ companies are developing over 20 cytomegalovirus (CMV) infection treatment therapies across various clinical development phases.
Day One Biopharmaceuticals Appoints Michael Vasconcelles as Head of R&D to Drive Pipeline Expansion
Day One Biopharmaceuticals has appointed Michael Vasconcelles, M.D., as Head of Research and Development, bringing over 25 years of oncology research and development expertise to the company.
Revolutionary Gene Therapy and BBB-Penetrating Treatments Transform Hunter Syndrome Treatment Landscape
RGX-121, a one-time gene therapy using AAV vector technology, is expected to receive regulatory approval in the second half of 2025, potentially offering lifelong benefits from a single infusion for Hunter Syndrome patients.
Frontotemporal Dementia Therapeutics Enter New Era as Gene and Antibody Therapies Advance Toward Market
Alector's Latozinemab (AL001) leads the frontotemporal dementia pipeline as a monoclonal antibody targeting progranulin deficiency, currently in pivotal Phase III trials with potential approval by 2026-2027.
GC Biopharma's Hunterase Shows Significant Efficacy in Phase 3 Trial for Hunter Syndrome
GC Biopharma's Phase 3 clinical trial results for Hunterase (idursulfase beta) in Hunter Syndrome patients have been published in Genetics in Medicine, demonstrating significant improvements in functional mobility and metabolic markers.